Genentech prices tissue-agnostic therapy at almost half the cost of Bayer's

After scoring FDA approval for its tissue-agnostic therapy Thursday, Genentech Inc. priced Rozlytrek entrectinib Friday at a wholesale acquisition cost of up to $17,050 per month, nearly half that of its only competitor.

Rozlytrek is approved to treat NTRK fusion-positive solid tumors; FDA approved Vitrakvi larotrectinib from Bayer AG (Xetra:BAYN) for the same indication in November (see "Genentech Gains its First U.S. Tissue-Agnostic Approval with Rozlytrek")...